Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safe Use workshop set

This article was originally published in The Tan Sheet

Executive Summary

FDA officials discuss the status of Safe Use Initiative activities and future projects at a public workshop in November. According to the agency's website, FDA will gather input and perspectives for directions toward the development of "collaborative, cross-sector safe medication use activities with healthcare stakeholders." FDA scheduled the meeting for Nov. 16, 8:30 a.m. to 4:45 p.m. EST, and Nov. 17, 8:30 a.m. to 12 p.m., in Silver Spring, Md. FDA launched the initiative in 2008 to reduce the likelihood of preventable injury and death caused by medical errors, unintentional exposure to drugs, misuse, abuse or attempts at self-harm (1"The Tan Sheet" May 10, 2010)
Advertisement

Related Content

Acetaminophen Awareness Coalition Prepares To Launch Education Campaign
Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress
Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress

Topics

Advertisement
UsernamePublicRestriction

Register

PS104544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel